UMB Bank n.a. Lowers Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

UMB Bank n.a. reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 0.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 279,419 shares of the company’s stock after selling 2,655 shares during the quarter. IDEXX Laboratories comprises 2.3% of UMB Bank n.a.’s holdings, making the stock its 7th largest position. UMB Bank n.a.’s holdings in IDEXX Laboratories were worth $155,092,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of IDXX. Panagora Asset Management Inc. grew its position in shares of IDEXX Laboratories by 50.3% during the 1st quarter. Panagora Asset Management Inc. now owns 3,232 shares of the company’s stock worth $1,768,000 after purchasing an additional 1,081 shares in the last quarter. Raymond James Trust N.A. grew its position in shares of IDEXX Laboratories by 26.8% during the 1st quarter. Raymond James Trust N.A. now owns 1,624 shares of the company’s stock worth $888,000 after purchasing an additional 343 shares in the last quarter. Cetera Investment Advisers grew its position in shares of IDEXX Laboratories by 77.1% during the 1st quarter. Cetera Investment Advisers now owns 3,675 shares of the company’s stock worth $2,010,000 after purchasing an additional 1,600 shares in the last quarter. Moors & Cabot Inc. grew its position in shares of IDEXX Laboratories by 3.0% during the 1st quarter. Moors & Cabot Inc. now owns 1,757 shares of the company’s stock worth $961,000 after purchasing an additional 52 shares in the last quarter. Finally, Sequoia Financial Advisors LLC grew its position in shares of IDEXX Laboratories by 15.6% during the 1st quarter. Sequoia Financial Advisors LLC now owns 992 shares of the company’s stock worth $543,000 after purchasing an additional 134 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Price Performance

IDXX stock opened at $524.04 on Thursday. The company has a fifty day moving average price of $548.68 and a 200-day moving average price of $504.25. The company has a market capitalization of $43.52 billion, a P/E ratio of 52.04, a PEG ratio of 2.86 and a beta of 1.26. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last released its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.20. The firm had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.05 earnings per share. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

Analyst Ratings Changes

IDXX has been the topic of several analyst reports. JPMorgan Chase & Co. increased their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research report on Friday, January 5th. BNP Paribas initiated coverage on shares of IDEXX Laboratories in a research report on Thursday, December 7th. They set an “outperform” rating and a $602.00 price target on the stock. The Goldman Sachs Group increased their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, Barclays raised their target price on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $591.50.

Check Out Our Latest Analysis on IDXX

Insider Activity

In related news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the transaction, the chief financial officer now owns 29,718 shares of the company’s stock, valued at $16,939,557.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,524 shares of company stock valued at $24,871,960. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Featured Articles

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.